Together, these studies suggest that PRDM16 protects against arterial disorders via its effect on ECs, PVAT cells, and SMCs, and that loss of PRDM16 invariably leads to transcriptional changes with associated pathogenic, maladaptive cell states that contribute to disease progression. Here, PRDM16 is linked to arterial disorder.